Financing ·
NeuroSense Therapeutics Ltd. entered into Amendment No. 1 to its Capital on Demand Sales Agreement with JonesTrading…
NRSNWNeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. entered into Amendment No. 1 to its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating references from a prior Form F-3 registration statement to a new one declared effective by the SEC on July 31, 2026. This amendment allows the company to offer and sell ordinary shares with an aggregate offering price of up to $3,789,822 under the existing agreement. As of the filing date, NeuroSense had sold 6,762,825 ordinary shares for net proceeds of approximately $6.7 million. The Sales Agreement remains in full force and effect except as amended. NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of therapeutic treatments.